[Application of immunochemical methods to the estimation of C3 and C5 hemolytic activity (author's transl)].
Explore the source record for details and available documents.
SEARCH · Search PubMed
Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
Explore the source record for details and available documents.
Complement component C5-deficient mice were found to be able to eliminate blood-borne Borrelia turicatae as effectively as normocomplementemic control animals. The absence of C5 and the resultant loss of hemolytic complement activity were confirmed for the deficient mouse strains used. Immunofluorescent staining of complement component C3 on blood-derived borreliae could be readily accomplished as early as 2 days before spirochetal elimination from all mice tested. These observations would suggest that C3 deposition was occurring, even though the terminal lytic steps were blocked in the complement-deficient mice. We propose that spirochetolysis is not requisite for successful removal of borreliae from the circulation of mice.
Serum C1q, C3, C4, and C5 components of complement levels were measured in 35 healthy subjects and 29 patients with acute conjunctivitis due to adenovirus type 2, 7, and 8 infections. Serum C1q and C3 levels were found to be significantly low, and there was no change in serum C4 and C5 levels. A progressive decline in the serum complement level with the severity of disease was observed. The change in the complement levels in serum showed a tendency to reach normal levels with clinical improvement.
Serum C1q, C3, C4, and C5 components of complement levels were measured in 56 healthy subjects and 98 patients with trachoma. Serum C1q and C3 levels were found to be significantly low in stages II and III. There was no change in serum C4 and C5 levels in any of the stages. The levels of C1q and C3 complement components in serum in stages II and III returned to normal as the disease resolved following the medical treatment.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.